Cat. No.
MABL-1073
Application
in vivo, therapeutic, FC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
2.8
From
Recombinant Antibody
Specificity
This antibody binds human CD69. CD69 (cluster of differentiation 69), a membrane bound type II C-lectin disulfide–linked homodimer receptor, which is expressed on different leukocytes, including newly- activated lymphocytes, certain subtypes of memory T-cells, infiltrating lymphocytes isolated from patients with chronic inflammatory disorders, and regulatory T-cells. It is involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets.
Alternative Names
AIM; BL-AC/P26; EA1; CLEC2C; GP32/28; MLR-3; Early activation antigen CD69; Activation inducer molecule; C-type lectin domain family 2 member C; Early T-cell activation antigen p60; Leukocyte surface antigen Leu-23
UniProt
Q07108
Immunogen
The original antibody was generated by fusing NS-1 myeloma cells with spleen cells from a CD69 (-/-) mouse that had previously been immunized 3 times with CD69 cells (pre-B 300-19 expressing the human CD69 molecule).
Application Notes
This antibody can be used for the analysis of CD69 expressed on the surface of cell surface using flow cytometry (PMID: 16983725). This antibody was used as a control antibody in in vivo mouse experiments as it does not bind mouse CD69 (PMID: 16983725; 27151919). This antibody was used in a study to show control on vaccinia virus (VACV) infection in both preventive and therapeutic treatment for transgenic mice expressing human CD69. Treatment in human-CD69 transgenic mouse model with the anti-huCD69-2.8 MAb could affect the primary adaptive response to VACV infection by increasing the number of activated T cells in the periphery (PMID: 31315995). In vivo CD69 targeting in mice expressing human CD69 induced rapid and massive mobilization of bone marrow leukocytes, which was inhibited by desensitization to S1P with FTY720. The treatment highly increased LSK and CLP cell proliferation and numbers, both in the periphery and in the bone marrow, and also augmented S1P1 and CXCR4 expression (PMID: 29483712).
Antibody First Published
Esplugues et al. Enhanced antitumor immunity in mice deficient in CD69. J Exp Med. 2003 May 5;197(9):1093-106. PMID:12732655
Note on publication
Describes the generation murine antibodies against mouse CD69 and evaluates their anti-tumor activity.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
